Novavax (NASDAQ:NVAX) on Wednesday announced late-stage trial data to indicate that its COVID-19-Influenza Combination (CIC) vaccine candidate and its stand-alone influenza vaccine candidate generated ...

The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United ...

Vaccine maker Novavax says its shot is highly effective against COVID-19 and also protects against variants. The Maryland-based company on Monday announced results from a large, late-stage study in ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that ...

(CNN) — After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. File Photo by Jim Lo Scalzo/EPA-EFE May 18 (UPI) --The U.S. Food and Drug ...

HOUSTON, Texas (KTRK) -- Pfizer and Moderna doses are making their way to cities across the country, but it's simply not enough to meet the need. "Right now, there's a huge demand for a limited supply ...

The biotechnology company Novavax plans to submit complete data to the US Food and Drug Administration soon for possible emergency use authorization of its coronavirus vaccine, CEO Stanley Erck told ...

NEW YORK (WABC) -- The biotechnology company Novavax plans to submit complete data to the US Food and Drug Administration soon for possible emergency use authorization of its coronavirus vaccine, CEO ...

Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional ...